- AR7
-
- $31.00
-
2026-06-02
- CAS:80306-38-3
- Purity: 99.67%
- Supply Ability: 10g
|
| Product Name: | AR7 | | Synonyms: | AR7;7-Chloro-3-(4-methylphenyl)-2H-1,4-benzoxazine;7-Chloro-3-p-tolyl-2H-benzo[b][1,4]oxazine;Atypical retinoid 7;Thyroid Hormone receptor,α1 human;c-ERBA-1;ERBA;ERB-T-1 | | CAS: | 80306-38-3 | | MF: | C15H12ClNO | | MW: | 257.71 | | EINECS: | | | Product Categories: | | | Mol File: | 80306-38-3.mol |  |
| storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | color | white to beige | | biological source | human | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. | | InChIKey | PUXHKTZKBDGXBB-UHFFFAOYSA-N | | SMILES | Clc1cc2c(cc1)NC(=CO2)c3ccc(cc3)C |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1
Aquatic Chronic 1 |
| Description | AR7 (80306-38-3) is an atypical retinoid which acts as an RARα antagonist and activates chaperone-mediated autophagy (CMA) via an RAR-dependent pathway.1 Downstream signaling results in an increase of LAMP-2A expression.1 Cells pretreated with AR7 had markedly improved viability in a paraquat-induced oxidative stress model.1 AR7 stimulated CMA and attenuated accumulation of SNCA oligomers in prolonged cultures of mutant cortical neurons2 indicating that CMA activation may be a viable disease modifying strategy in Parkinson’s disease3. A targetome analysis of AR7-induced CMA in cancer cells has been performed.4 | | Uses | AR 7 is a CMA booster. Used in biological study of chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. | | References | [1] JAIME ANGUIANO. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives[J]. Nature chemical biology, 2013, 9 6: 374-382. DOI:10.1038/nchembio.1230
[2] PHILIP WING-LOK HO. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).[J]. Autophagy, 2020, 16 2: 347-370. DOI:10.1080/15548627.2019.1603545
[3] SRINIVASA REDDY BONAM Sylviane M Christine Tranchant. Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease.[J]. ACS Applied Materials & Interfaces, 2021. DOI:10.3390/cells10123547
[4] YUQING HAO. Targetome analysis of chaperone-mediated autophagy in cancer cells.[J]. Autophagy, 2019: 1558-1571. DOI:10.1080/15548627.2019.1586255 |
| | AR7 Preparation Products And Raw materials |
|